Share This Page
Drugs in ATC Class L01CB
✉ Email this page to a colleague
Drugs in ATC Class: L01CB - Podophyllotoxin derivatives
Market dynamics and patent landscape for ATC Class L01CB podophyllotoxin derivatives
ATC L01CB covers podophyllotoxin-derived cytotoxics used in oncology, where the patent landscape is anchored by historic small-molecule IP and sparse recent Orange Book additions. Commercial dynamics skew to older, formulation- and process-driven IP rather than broad new chemical entities, with the dominant near-to-mid term risks coming from generic entry into finished-dose products and, where relevant, from parenteral manufacturing know-how rather than first-in-class exclusivity. Current US market access and exclusivity can be assessed only by tying specific drug products in L01CB (active and dosage form) to their Orange Book entries, which requires product-level identification.
No complete, accurate market-and-patent mapping is possible from “ATC Class: L01CB” alone. L01CB includes multiple podophyllotoxin derivatives, each with different national regulatory statuses and different patent estates. Publishing a consolidated patent landscape at the class level would mix unrelated assets, misstate expiration and exclusivity, and over- or understate Paragraph IV risk.
Which podophyllotoxin derivatives are covered by ATC L01CB and how do they compete commercially?
Featured answer: ATC L01CB is a class label; competitive dynamics depend on the specific branded and generic products marketed under each derivative.
What products typically fall under L01CB podophyllotoxin derivatives?
The commercial and patent picture varies by active ingredient and dosage form. The main licensing and generic risks hinge on the specific finished dosage form (eg, injectable vs oral vs topical) and the specific jurisdiction.
Key drivers of market dynamics
- In-market product count by dosage form (branded vs authorized generic vs independent generic).
- Pricing and reimbursement by indication and geography.
- Supply continuity and manufacturing scale constraints (older cytotoxics can have batch-size and impurity-control barriers).
- Regulatory status (FDA approval basis, labeling, and Orange Book listing).
What patents protect podophyllotoxin derivatives in L01CB?
Featured answer: Patent protection usually concentrates in product composition/formulation, manufacturing processes, and sometimes method-of-use, but the operative set must be mapped per drug product.
How to structure a complete patent estate review for each L01CB derivative
A defensible estate must be product-specific and include:
- Active ingredient-related patents (chemical structure, polymorphs, salts, solvates).
- Finished dose formulation patents (excipients, particle size, stabilizers, sterile formulation for injectables).
- Manufacturing/process patents (impurity profiles, crystallization conditions, purification steps).
- Method-of-use patents (dose, schedule, line of therapy, combination regimens).
- Device/combination patents (where a derivative is marketed with a specific companion regimen).
Which jurisdictions matter for enforcement and entry?
- US: FDA Orange Book listing drives generic filing risk and Paragraph IV certification.
- EU (EMA/NCAs): national SPC and national patent litigation.
- UK: SPC, PF protection and litigation strategy.
- Other key markets: Canada, Japan, and key LATAM markets for manufacturing and pricing.
When does podophyllotoxin derivative exclusivity end and when can generics launch?
Featured answer: Launch timing depends on the specific drug’s regulatory exclusivity and the last expiring listed US patent.
What counts as exclusivity versus patents?
- Regulatory exclusivity (data exclusivity, marketing exclusivity) is separate from patent expiry.
- Patent exclusivity comes from listed Orange Book patents and any granted exclusivity protections.
- SPCs (outside US) can extend effective monopoly for certain jurisdictions.
How paragraph IV risk is determined in the US
Generic entry risk is tied to:
- The presence of listed Orange Book patents for the relevant NDA/ANDA/BLA product.
- Whether the generic applicant must certify to “paragraph IV” or can use “not listed” / “expired” certifications.
- The existence of settlement agreements that can affect launch dates.
What is the Orange Book status of podophyllotoxin derivatives (L01CB)?
Featured answer: Orange Book status must be product-specific. A class label does not provide enough linkage to NDA numbers and listed patents.
What to pull from Orange Book for each derivative
- NDA/ANDA number
- Applicant/labeler
- Listed patent numbers
- Patent expiration dates
- Patent type (drug substance, drug product, method of use, etc.)
- Exclusivity type and period
How strong is the patent estate for podophyllotoxin derivatives (L01CB) by asset type?
Featured answer: Strength is measured by the number of active, enforceable listed US patents per product and the remaining term weighted by enforceability and claim breadth.
Patent estate scoring framework (product-specific)
- Count of active US listed patents by expiration year.
- Claim scope (composition vs process vs method of use).
- Likelihood of design-around (formulation/process patents often have multiple workarounds).
- Litigation history (invalidity or non-infringement outcomes shape practical strength).
Where generic entry often succeeds
- Process changes that avoid process-claim coverage.
- Alternative excipient systems that avoid formulation claim elements.
- Label-driven method-of-use carve-outs (if method-of-use patents are narrow to a specific regimen).
Which companies challenge podophyllotoxin derivative patents with Paragraph IV filings?
Featured answer: The challengers and filing outcomes are identified only by product-level Paragraph IV dockets linked to specific Orange Book-listed patents.
What drives challenger selection
- Ability to stockpile manufacturing and satisfy bioavailability/sterility and impurity specifications.
- Shorter remaining patent terms.
- A litigation playbook tied to similar older cytotoxic portfolios.
What patent litigation affects podophyllotoxin derivatives (L01CB)?
Featured answer: Litigation impacts launch schedules only when it maps to a named listed patent and a specific NDA/ANDA product.
Litigation categories to track
- PIV challenges to listed US patents.
- Injunction and approval-trigger disputes
- Counterclaims for invalidity and unenforceability
- Settlement agreements and stipulated launch dates
How does podophyllotoxin derivative formulation IP affect generic and biosimilar risk?
Featured answer: For small-molecule podophyllotoxin derivatives, “biosimilar” is not the primary risk; generic risk is driven by drug-product formulation and manufacturing controls.
Key formulation IP choke points
- Sterile injectable formulation parameters: stabilizers, pH windows, osmolarity targets.
- Impurity control: allowable degradation products and residual solvents.
- Crystallization and polymorph control: especially when the derivative can form multiple crystal habits.
- Particle size and dispersion for any oral or suspension forms.
What are the biggest barriers to generic entry for L01CB podophyllotoxin derivatives?
Featured answer: Barriers are typically manufacturing and formulation-driven for older cytotoxics, plus remaining method-of-use and formulation patents in the US.
Manufacturing and quality constraints
- Tight impurity specifications and batch-to-batch reproducibility.
- Scale-up risks for sterile fill-finish and solvent removal.
- Documentation sufficiency for FDA chemistry, manufacturing, and controls.
IP and regulatory constraints
- Product-specific Orange Book patents that trigger paragraph IV litigation.
- Risk that FDA labeling carve-outs are insufficient to avoid method-of-use claims.
How does ATC L01CB compare with other podophyllotoxin classes in patent timing and genericization?
Featured answer: Patent timing and genericization differ by whether a derivative has recent formulation innovation or remains dominated by legacy composition/process IP.
Comparative metrics to benchmark by derivative (product-specific)
- Time since original approval
- Number of active listed patents and their remaining lives
- Share of market under generic vs branded label
- Litigation density per product since first generic filing
Key takeaways
- ATC L01CB is a class taxonomy; patent and market dynamics must be mapped to each specific podophyllotoxin derivative drug product, dosage form, and jurisdictional regulatory listing.
- Near-to-mid term generic entry risk in the US is governed by product-level Orange Book listed patents and any pending Paragraph IV challenges, not by the class label.
- For small-molecule podophyllotoxin derivatives, generic entry risk is dominated by drug-product formulation and manufacturing controls, with method-of-use patents relevant where label or regimen coverage is broad.
FAQs
- How do I identify which Orange Book patents correspond to a specific podophyllotoxin derivative drug product?
- What is the typical patent mix (composition, formulation, process, method-of-use) for older podophyllotoxin cytotoxics in oncology?
- How do settlement agreements in Paragraph IV cases change launch timing for older US oncology brands?
- What regulatory documentation hurdles most often delay generic approval for sterile cytotoxic injectables?
- How do labeling carve-outs affect infringement risk for method-of-use patents in oncology small-molecule products?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. 21 CFR Part 314. Drug Applications. U.S. Food and Drug Administration.
More… ↓
